Blood glucose monitors and test strips are product areas that may fall under a competitive bidding model in upcoming Medicare reform legislation, according to device stakeholders

The passage of a Medicare prescription drug benefit in the 108th Congress could lead to the expansion of competitive bidding processes beyond durable medical equipment to include non-DME devices, consultants and industry reps are forecasting

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.